Cargando…
The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
Recently, we have shown that the administration of the tumour-targeted antibody-based immunocytokine L19-IL2 after radiotherapy (RT) resulted in synergistic anti-tumour effect. Here we show that RT and L19-IL2 can activate a curative abscopal effect, with a long-lasting immunological memory. Ionizin...
Autores principales: | Rekers, Nicolle H., Olivo Pimentel, Veronica, Yaromina, Ala, Lieuwes, Natasja G., Biemans, Rianne, Zegers, Catharina M. L., Germeraad, Wilfred T. V., Van Limbergen, Evert J., Neri, Dario, Dubois, Ludwig J., Lambin, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889197/ https://www.ncbi.nlm.nih.gov/pubmed/29632732 http://dx.doi.org/10.1080/2162402X.2017.1414119 |
Ejemplares similares
-
Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2
por: Rekers, Nicolle H, et al.
Publicado: (2015) -
Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19–IL2 cures poorly immunogenic tumors when combined with radiotherapy
por: Olivo Pimentel, Veronica, et al.
Publicado: (2021) -
Combining radiotherapy with immunotherapy: the past, the present and the future
por: Van Limbergen, Evert J, et al.
Publicado: (2017) -
In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity
por: Panth, Kranthi Marella, et al.
Publicado: (2016) -
Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity
por: Spiegelberg, Linda, et al.
Publicado: (2019)